Hip region muscular dystrophy and emergence of motor deficits in dysferlin-deficient Bla/J mice

Physiological Reports

Volumn 5, Issue 6, 2017, Pages

  Nagy, Nadia ^a   Nonneman, Randal J ^a   Llanga, Telmo ^a   Dial, Catherine F ^a   Riddick, Natallia V ^a   Hampton, Tom ^b   Moy, Sheryl S ^a   Lehtimäki, Kimmo K ^c   Ahtoniemi, Toni ^c   Puoliväli, Jukka ^c   Windish, Hillarie ^d   Albrecht, Douglas ^d   Richard, Isabelle ^e   Hirsch, Matthew L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Mouse Specifics Inc   (United States)

^c Charles River Discovery Research Services   (Finland)

^d Jain Foundation Inc   (United States)

^e GÉNÉTHON   (France)

Author keywords

Bla J; dysferlin; locomotor deficits; mouse model; muscular MR imaging and spectroscopy

Indexed keywords

CREATINE KINASE; DYSFERLIN; DYSF PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; CELL METABOLISM; CONTROLLED STUDY; DISEASE COURSE; DYSFERLINOPATHY; EXPLORATORY BEHAVIOR; FEMALE; GAIT; GLUTEUS MAXIMUS MUSCLE; GRIP STRENGTH TEST; LIFE EXPECTANCY; MALE; MARBLE BURYING TEST; MORRIS WATER MAZE TEST; MOTOR DYSFUNCTION; MOTOR FUNCTION TEST; MOTOR PERFORMANCE; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN FIELD TEST; PROTON NUCLEAR MAGNETIC RESONANCE; PSOAS MUSCLE; REARING; ROTAROD TEST; SWIMMING; TREADMILL TEST; ANIMAL; DIAGNOSTIC IMAGING; DISEASE MODEL; GENETICS; HIP; KNOCKOUT MOUSE; LIMB GIRDLE MUSCULAR DYSTROPHY; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

ANIMALS; DISEASE MODELS, ANIMAL; DYSFERLIN; FEMALE; GAIT; HIP; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHIES, LIMB-GIRDLE;

EID: 85016321349     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.13173     Document Type: Article

References (39)

1. Aoki, M. Dysferlinopathy. 1993. In R. A. Pagon, M. P. Adam, H. H. Ardinger, S. E. Wallace, A. Amemiya, L. J. H. Bean, T. D. Bird, C. T. Fong, H. C. Mefford, R. J. H. Smith, K. Stephens. GeneReviews(R). GeneReviews, Seattle (WA).
2. Armstrong, N., and A. R. Barker. 2009. Oxygen uptake kinetics in children and adolescents: a review. Pediatr. Exerc. Sci. 21:130–147.
3. Bansal, D., K. Miyake, S. S. Vogel, S. Groh, C. C. Chen, R. Williamson, et al. 2003. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423:168–172.
4. Bernard, C. C., and P. R. Carnegie. 1975. Experimental autoimmune encephalomyelitis in mice: immunologic response to mouse spinal cord and myelin basic proteins. J. Immunol. 114:1537–1540.
5. Bittner, R. E., L. V. Anderson, E. Burkhardt, R. Bashir, E. Vafiadaki, S. Ivanova, et al. 1999. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat. Genet. 23:141–142.
6. Brussee, V., F. Tardif, and J. P. Tremblay. 1997. Muscle fibers of mdx mice are more vulnerable to exercise than those of normal mice. Neuromuscul. Disord. 7:487–492.
7. Dominov, J. A., O. Uyan, P. C. Sapp, D. McKenna-Yasek, B. R. Nallamilli, M. Hegde, et al. 2014. A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides. Ann. Clin. Transl. Neurol. 1:703–720.
8. Glover, L., and R. H. Brown, Jr. 2007. Dysferlin in membrane trafficking and patch repair. Traffic 8:785–794.
9. Grose, W. E., K. R. Clark, D. Griffin, V. Malik, K. M. Shontz, C. L. Montgomery, et al. 2012. Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS ONE 7:e39233.
10. Grounds, M. D., J. R. Terrill, H. G. Radley-Crabb, T. Robertson, J. Papadimitriou, S. Spuler, et al. 2014. Lipid accumulation in dysferlin-deficient muscles. Am. J. Pathol. 184:1668–1676.
11. Hampton, T. G., and I. Amende. 2010. Treadmill gait analysis characterizes gait alterations in Parkinson's disease and amyotrophic lateral sclerosis mouse models. J. Mot. Behav. 42:1–4.
12. Hampton, T. G., M. R. Stasko, A. Kale, I. Amende, and A. C. Costa. 2004. Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome. Physiol. Behav. 82:381–389.
13. Hirsch, M. L., C. Li, I. Bellon, C. Yin, S. Chavala, M. Pryadkina, et al. 2013. Oversized AAV transductifon is mediated via a DNA-PKcs-independent, Rad51C-dependent repair pathway. Mol. Ther. 21:2205–2216.
14. Ho, M., C. M. Post, L. R. Donahue, H. G. Lidov, R. T. Bronson, H. Goolsby, et al. 2004. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum. Mol. Genet. 13:1999–2010.
15. Hornsey, M. A., S. H. Laval, R. Barresi, H. Lochmuller, and K. Bushby. 2013. Muscular dystrophy in dysferlin-deficient mouse models. Neuromuscul. Disord. 23:377–387.
16. Hosur, V., A. Kavirayani, J. Riefler, L. M. Carney, B. Lyons, B. Gott, et al. 2012. Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma. Cancer Genet. 205:232–241.
17. Kale, A., I. Amende, K. Piskorski, V. Chu, J. M. Otero, P. Mueller, et al. 2004. Non-invasive physiology in conscious mice. Altern. Lab. Anim. 32(Suppl 1A):195–201.
18. Keller, S. 2014. GC/MS and LC/MS based metabolic and proteomic analysis of dysferlin deficient muscle from patients and animal models. Pp. 91. in Medicine. Berlin Medizinische Fakultät Charité - Universitätsmedizin Berlin. Available at: http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000095525.
19. Krahn, M., C. Beroud, V. Labelle, K. Nguyen, R. Bernard, G. Bassez, et al. 2009. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum. Mutat. 30:E345–E375.
20. Lostal, W., M. Bartoli, N. Bourg, C. Roudaut, A. Bentaib, K. Miyake, et al. 2010. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum. Mol. Genet. 19:1897–1907.
21. Maddatu, T. P., S. M. Garvey, D. G. Schroeder, T. G. Hampton, and G. A. Cox. 2004. Transgenic rescue of neurogenic atrophy in the nmd mouse reveals a role for Ighmbp2 in dilated cardiomyopathy. Hum. Mol. Genet. 13:1105–1115.
22. Mahjneh, I., G. Marconi, K. Bushby, L. V. Anderson, H. Tolvanen-Mahjneh, and H. Somer. 2001. Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations. Neuromuscul. Disord. 11:20–26.
23. deMorree, A., B. Flix, I. Bagaric, J. Wang, vanden Boogaard M., L. Grand Moursel, et al. 2013. Dysferlin regulates cell adhesion in human monocytes. J. Biol. Chem. 288:14147–14157.
24. Petersen, J. A., T. Kuntzer, D. Fischer, M. von der Hagen, A. Huebner, V. Kana, et al. 2015. Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects. BMC Neurol. 15:182.
25. Pryadkina, M., W. Lostal, N. Bourg, K. Charton, C. Roudaut, M. L. Hirsch, et al. 2015. A comparison of AAV strategies distinguishes overlapping vectors for efficient systemic delivery of the 6.2 kb Dysferlin coding sequence. Mol. Ther. Methods Clin. Dev. A 2:15009.
26. Rayavarapu, S., J. H. Van der Meulen, H. Gordish-Dressman, E. P. Hoffman, K. Nagaraju, and S. M. Knoblach. 2010. Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. PLoS ONE 5:e12981.
27. Rhodes, J. C., L. S. Wicker, and W. J. Urba. 1980. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect. Immun. 29:494–499.
28. Schmidt, W. M., M. H. Uddin, S. Dysek, K. Moser-Thier, C. Pirker, H. Hoger, et al. 2011. DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies. PLoS Genet. 7:e1002042.
29. Sher, R. B., G. A. Cox, K. D. Mills, and J. P. Sundberg. 2011. Rhabdomyosarcomas in aging A/J mice. PLoS ONE 6:e23498.
30. Sondergaard, P. C., D. A. Griffin, E. R. Pozsgai, R. W. Johnson, W. E. Grose, K. N. Heller, et al. 2015. Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models. Ann. Clin. Transl. Neurol. 2:256–270.
31. Stephens, B. R., A. S. Cole, and A. D. Mahon. 2006. The influence of biological maturation on fat and carbohydrate metabolism during exercise in males. Int. J. Sport Nutr. Exerc. Metab. 16:166–179.
32. Taylor, D. J., G. J. Kemp, C. H. Thompson, and G. K. Radda. 1997. Ageing: effects on oxidative function of skeletal muscle in vivo. Mol. Cell. Biochem. 174:321–324.
33. Timmons, B. W., O. Bar-Or, and M. C. Riddell. 2003. Oxidation rate of exogenous carbohydrate during exercise is higher in boys than in men. J. Appl. Physiol. 94:278–284.
34. Timmons, B. W., O. Bar-Or, and M. C. Riddell. 2007. Influence of age and pubertal status on substrate utilization during exercise with and without carbohydrate intake in healthy boys. Appl. Physiol. Nutr. Metab. 32:416–425.
35. Ueyama, H., T. Kumamoto, H. Horinouchi, S. Fujimoto, H. Aono, and T. Tsuda. 2002. Clinical heterogeneity in dysferlinopathy. Intern. Med. 41:532–536.
36. Wein, N., A. Avril, M. Bartoli, C. Beley, S. Chaouch, P. Laforet, et al. 2010. Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum. Mutat. 31:136–142.
37. Weller, A. H., S. A. Magliato, K. P. Bell, and N. L. Rosenberg. 1997. Spontaneous myopathy in the SJL/J mouse: pathology and strength loss. Muscle Nerve 20:72–82.
38. Whitehead, C. L., S. J. Hillman, A. M. Richardson, M. E. Hazlewood, and J. E. Robb. 2007. The effect of simulated hamstring shortening on gait in normal subjects. Gait Posture. 26:90–96.
39. Wiktorowicz, T., J. Kinter, K. Kobuke, K. P. Campbell, and M. Sinnreich. 2015. Genetic characterization and improved genotyping of the dysferlin-deficient mouse strain Dysf (tm1Kcam). Skelet. Muscle 5:32.